SCHEMBL6004979

SCHEMBL6004979

NC(=O)[C@@H]1N=C(c2ccccc2F)c2ccccc2N(CC(F)(F)F)C1=O

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.44
CCKBR P32239 12/20 0.44
CCKAR P32238 10/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6003776 0.84 GABRP (0.44) KCNH2CCKBRCCKAR
SCHEMBL6004989 0.84 GABRP (0.44) KCNH2CCKBRCCKAR
SCHEMBL6003648 0.77 CCKAR (0.44) CCKBRCCKAR
SCHEMBL8846479 0.74 CCKBR (0.64) KCNH2CCKBRCCKAR
SCHEMBL7871697 0.73 CYP3A4 (0.55) KCNH2CCKBRCCKAR
SCHEMBL7212252 0.73 CCKAR (0.64) KCNH2CCKBRCCKAR
SCHEMBL4701488 0.72 GABRP (0.50) CCKBRCCKAR
SCHEMBL11471406 0.72 OPRK1 (0.52) KCNH2CCKBRCCKAR
SCHEMBL11464229 0.72 CCKAR (0.39) KCNH2CCKBRCCKAR
SCHEMBL9525412 0.71 CCKBR (0.76) CCKBRCCKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP KCNH2 1795/4885CCKBR 642/4885CCKAR 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.